Medicinal Chemistry Expertise
Califia Bio, Inc. has been awarded a Michael J. Fox Foundation Research grant to investigate the efficacy of CLFB-1134 in animal models of Parkinson’s Disease.
Previously, inhibitors of mixed lineage kinase 3 (MLK3) showed great promise for treatment of Parkinson’s disease in pre-clinical models, but interest in this area halted when a non-selective inhibitor (CEP-1347) failed in Phase II clinical trials. We have investigated the poor target specificity and poor ability of CEP-1347 to penetrate the blood-brain barrier1 and have developed new compounds with much higher selectivity for MLK3 and much improved ability to achieve high concentrations in the brain.
We are seeking partners to develop and commercialize orally active, brain penetrant and highly selective MLK3 inhibitor compounds for potential treatments for Parkinson’s Disease, Post- Operative Cognitive Dysfunction (POCD) and HIV-Associated Neurocognitive Disorders.